Boston Scientific Corporation (NYSE:BSX) – Research analysts at SunTrust Banks lifted their Q1 2018 earnings estimates for Boston Scientific Corporation in a report issued on Thursday. SunTrust Banks analyst B. Nudell now expects that the medical equipment provider will post earnings per share of $0.33 for the quarter, up from their prior forecast of $0.31. SunTrust Banks has a “Buy” rating and a $34.00 price objective on the stock. SunTrust Banks also issued estimates for Boston Scientific Corporation’s Q3 2018 earnings at $0.34 EPS and FY2018 earnings at $1.43 EPS.

Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.31. Boston Scientific Corporation had a net margin of 9.55% and a return on equity of 23.60%. The business had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.21 billion. During the same period in the prior year, the business posted $0.27 earnings per share. Boston Scientific Corporation’s revenue for the quarter was up 5.6% compared to the same quarter last year.

COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/30/suntrust-banks-weighs-in-on-boston-scientific-corporations-q1-2018-earnings-bsx.html.

Several other research firms have also recently commented on BSX. Canaccord Genuity assumed coverage on shares of Boston Scientific Corporation in a research report on Tuesday, October 24th. They issued a “buy” rating and a $36.00 price objective on the stock. Zacks Investment Research raised shares of Boston Scientific Corporation from a “sell” rating to a “buy” rating and set a $33.00 price objective on the stock in a research report on Friday, October 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Boston Scientific Corporation in a research report on Tuesday, October 3rd. BMO Capital Markets reiterated a “buy” rating and issued a $30.00 price target on shares of Boston Scientific Corporation in a research note on Friday, October 13th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $32.00 price target on shares of Boston Scientific Corporation in a research note on Monday, September 25th. One research analyst has rated the stock with a sell rating, four have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $30.77.

Boston Scientific Corporation (NYSE:BSX) opened at 28.50 on Monday. Boston Scientific Corporation has a 1-year low of $19.67 and a 1-year high of $29.93. The firm has a market capitalization of $39.11 billion, a P/E ratio of 50.98 and a beta of 1.09. The stock has a 50 day moving average of $29.14 and a 200-day moving average of $27.51.

In other news, SVP Wendy Carruthers sold 12,433 shares of the business’s stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $26.75, for a total transaction of $332,582.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP John Bradley Sorenson sold 7,900 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $26.37, for a total transaction of $208,323.00. Following the completion of the transaction, the senior vice president now owns 21,680 shares in the company, valued at approximately $571,701.60. The disclosure for this sale can be found here. Insiders have sold a total of 513,697 shares of company stock worth $14,666,565 over the last 90 days. 0.74% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Comerica Securities Inc. grew its stake in Boston Scientific Corporation by 0.9% in the 2nd quarter. Comerica Securities Inc. now owns 11,478 shares of the medical equipment provider’s stock valued at $318,000 after buying an additional 99 shares during the last quarter. ETRADE Capital Management LLC grew its stake in Boston Scientific Corporation by 1.7% in the 2nd quarter. ETRADE Capital Management LLC now owns 10,079 shares of the medical equipment provider’s stock valued at $279,000 after buying an additional 171 shares during the last quarter. BB&T Corp grew its stake in Boston Scientific Corporation by 2.8% in the 2nd quarter. BB&T Corp now owns 12,926 shares of the medical equipment provider’s stock valued at $359,000 after buying an additional 349 shares during the last quarter. Krilogy Financial LLC grew its stake in Boston Scientific Corporation by 5.9% in the 2nd quarter. Krilogy Financial LLC now owns 7,680 shares of the medical equipment provider’s stock valued at $213,000 after buying an additional 430 shares during the last quarter. Finally, Wetherby Asset Management Inc. grew its stake in Boston Scientific Corporation by 3.9% in the 2nd quarter. Wetherby Asset Management Inc. now owns 13,788 shares of the medical equipment provider’s stock valued at $382,000 after buying an additional 523 shares during the last quarter. Institutional investors and hedge funds own 90.47% of the company’s stock.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Earnings History and Estimates for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.